Dr. Pendleton B. Wickersham, M.D.
Rheumatology (Rheumatology Physician)
- Medicare participating
At a glance
- Medical school
- Baylor College of Medicine (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 663
Licensed in Texas since 2006, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: Baylor College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
TX license M3113 (first issued 2006; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baptist Medical Center San Antonio, TX
Medical groups
- The West Texas Rehabilitation Center (466 clinicians)
- Arthritis Associates, P.a. (6 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 663
- Services billed
- 222,454
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Injection, tocilizumab, 1 mg | 57,827 | 13 |
| Injection, anifrolumab-fnia, 1 mg | 44,742 | 29 |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 37,200 | 14 |
| Injection, denosumab, 1 mg | 7,923 | 81 |
| Injection, rituximab, 10 mg | 2,410 | 13 |
| Established patient office or other outpatient visit, 30-39 minutes | 2,150 | 613 |
| Measurement of antibody for assessment of autoimmune disorder, any method | 1,536 | 160 |
| Insertion of needle into vein for collection of blood sample | 1,246 | 496 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,032 | 459 |
| Blood test, comprehensive group of blood chemicals | 1,024 | 468 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in San Antonio, TX | 685 |
| Prednisone Other prescribers in San Antonio, TX | 467 |
| Hydroxychloroquine Sulfate Other prescribers in San Antonio, TX | 464 |
| Methotrexate (methotrexate sodium) Other prescribers in San Antonio, TX | 305 |
| Gabapentin Other prescribers in San Antonio, TX | 225 |
| Duloxetine Hcl Other prescribers in San Antonio, TX | 195 |
| Levothyroxine Sodium Other prescribers in San Antonio, TX | 149 |
| Celecoxib Other prescribers in San Antonio, TX | 105 |
| Tramadol Hcl Other prescribers in San Antonio, TX | 104 |
| Tizanidine Hcl Other prescribers in San Antonio, TX | 97 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 16 companies reported 152 payments worth $14,266 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $7,511 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $5,060 |
| Janssen Biotech, Inc. | $342 |
| Novartis Pharmaceuticals Corporation | $328 |
| Amgen Inc. | $315 |
| GlaxoSmithKline, LLC. | $248 |
| AbbVie Inc. | $231 |
| UCB, Inc. | $57.98 |
| Consulting Fee | $9,668 |
|---|---|
| Food and Beverage | $2,302 |
| Compensation for services other than consulting (speaking, faculty) | $1,400 |
| Travel and Lodging | $796 |
| Education | $99.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Sep 15, 2025 | Consulting Fee | $6,413 |
| AstraZeneca Pharmaceuticals LP Nov 3, 2025 | Consulting Fee | $1,860 |
| AstraZeneca Pharmaceuticals LP Jan 8, 2025 | Compensation for services other than consulting (speaking, faculty) SAPHNELO · Inflammation and Autoimmunity Company’s descriptionSpeaker Fee | $1,400 |
| AstraZeneca Pharmaceuticals LP Feb 2, 2025 | Consulting Fee | $1,395 |
| E.r. Squibb & Sons, L.l.c. Sep 6, 2025 | Travel and Lodging travel to Denver, CO | $449 |
| E.r. Squibb & Sons, L.l.c. Sep 5, 2025 | Travel and Lodging travel to Denver, CO | $311 |
| Janssen Biotech, Inc. Sep 24, 2025 | Education TREMFYA · Immunology · in-kind | $99.99 |
| E.r. Squibb & Sons, L.l.c. Oct 7, 2025 | Travel and Lodging travel to DENVER, CO | $34.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $144,563 in research payments for these studies, mostly to the institutions running them.
- A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants
Amgen Inc. - A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment
AstraZeneca UK Limited - M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE)
AbbVie Inc. - A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
Eli Lilly and Company · Completed · NCT03915964 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
AbbVie Inc. · Active, not recruiting · NCT05843643 - Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
Sun Pharmaceutical Industries Inc. - INSPIRE LTE study
Sun Pharmaceutical Industries Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.